MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Type 2 diabetes prevention

  • Home
  • Type 2 diabetes prevention
Posted inDiabetes & Endocrinology news Public Health

Time-Restricted Eating vs Dietetic Guidance for Glycaemic Outcomes in Adults at Risk of Type 2 Diabetes

Posted by By MedXY 06/17/2026
Time-restricted eating performed similarly to individualized dietetic guidance for short-term HbA1c change in adults at risk of type 2 diabetes, but non-inferiority was not confirmed at 12 months. Benefits were small, and adverse events were minor.
Read More
Metformin with or without Mediterranean Diet Significantly Reduces Diabetes Risk in Metabolic Syndrome: Insights from the MeMeMe Trial
Posted inDiabetes & Endocrinology Family Medicine & Nutrition Specialties

Metformin with or without Mediterranean Diet Significantly Reduces Diabetes Risk in Metabolic Syndrome: Insights from the MeMeMe Trial

Posted by By MedXY 09/16/2025
The MeMeMe randomized trial shows that metformin 1,700 mg/day effectively prevents type 2 diabetes in metabolic syndrome patients, independent of Mediterranean diet adherence, with implications for age-related disease prevention.
Read More
  • Graft Choice Does Not Influence Revision ACL Reconstruction Risk in Football Players: Insights from a Swedish Nationwide Cohort
  • Sibeprenlimab Demonstrates Kidney Function Preservation in IgA Nephropathy: Insights from the Final Phase 3 VISIONARY Trial
  • Optical Coherence Tomography as a Prognostic Biomarker in Multiple Sclerosis: Insights from the American Academy of Ophthalmology Report
  • Predicting Surgical Success in Pediatric Obstructive Sleep Apnea: Insights from Weighted Analysis of Tonsillectomy Outcomes
  • Multimodal Prediction in Robotic Surgery: Evaluating the Added Value of Task-Level Kinematic Metrics
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation ischemic stroke MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top